FDA labeling for the weight-management indications generally covers adults with: A BMI of 30 or higher , or A BMI of 27 or higher with at least one weight-related condition type 2 diabetes, prediabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease But BMI is a starting filter, not the decision
By increasing insulin secretion, reducing glucagon production, and delaying gastric emptying, semaglutide promotes satiety, aiding in glycemic control and weight loss [4]
At the higher 7.2 mg dose, the STEP UP trial points to around 20kg for the same person, close to Mounjaros result
Recent data from the Centers for Disease Control and Prevention (CDC) gives us a clear snapshot of who is using these injectable medications
PMID: 23524641